多项研究获CSCO2020年度

中国临床肿瘤学优秀论文

CSCO候任理事长、中山大学肿瘤防治中心徐瑞华教授宣读了“2020年度中国临床肿瘤学优秀文”获奖名单。中国医学科学院肿瘤医院王洁教授领衔研

究获得优秀论文一等奖；东部战区总医院秦叔逵教授、同济大学附属东方医院李进教授领衔研究与北京大学肿瘤医院郭军教授、盛锡楠教授领衔研究荣获优秀论文二等奖；北京大学肿瘤医院沈琳教授等的七项研究荣获优秀论文三等奖。

RATIONALE 307: Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone

as First-line（1L）Treatment for AdvancedSquamous Non-Small Cell Lung Cancer（sqNSCLC）Jie Wang, Shun Lu, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu ,Chunhong Hu, Kunyu Yang, Guosheng Feng, Keijing Ying, Wu Zhuang, Jianying Zhou ,Jingxun Wu, Shiangjiin Leaw, Jing Zhang, Xiao Lin, Liang Liang, Nong Yang

1. HLX04, A Bevacizumab Biosimilar, Versus Reference Bevacizumab in Combination with

XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: A Phase 3 Study Shukui Qin, Jin Li, Yuxian Bai, Yongqian Shu, Wei Li, Xianli Yin, Ying Cheng, Guoping Sun,Yanhong Deng, Haijun Zhong, Yunfeng Li, Xiaoping Qian, Liangming Zhang, Jingdong Zhang,Kehe Chen, Yuping Sun, Yuan LinTianshu Liu, Li Bai, Shirong Cai Zong,Helong

Zhang, Wei Wang, Sanyuan Sun, Xiong, Jianfeng Zhou, Bangwei Cao,Hongming Pan,

Suxia Luo, Yi Ba, Nong Xu, Liman Zhang, Wei Li, Weidong Jiang,Scott Liu, Katherine Chai

2.一项考察特瑞普利单抗注射液（重组人源化抗PD-1 单克隆抗体注射液，JS001）在标准治疗失败后的局部进展或转移性膀胱尿路上皮癌患者中的有效性和安全性的开放、多中心、单臂、Ⅱ期临床研究（POLARIS-03）盛锡楠，陈海戈，胡滨，刘子玲，姚旭东，姚欣，郭宏骞，纪志刚，胡毅，刘继彦，史本康，罗宏，周芳坚，吴瑾，何志嵩，黄翼然，上海君实生物，郭军

1.Envafolimab（KN035）单药治疗MSI-H/dMMR 晚期实体瘤的有效性和安全性的

单臂、多中心Ⅱ期研究

沈琳，李健，邓艳红，张伟杰，周爱萍，郭伟剑，杨建伟，袁瑛，朱梁军，秦叔逵，向思

龙，鲁浩兰，龚兆龙，徐霆，刘东方

 2.Safety and patient-reported outcomes （PRO） with atezolizumab （atezo） +

bevacizumab（bev）vs sorafenib（sor）in Chinese patients（pts）with unresectable

HCC in IMbrave150 Shukui Qin, Zhenggang Ren, Haitao Zhao, Baocheng Wang, Yuxian Bai, ShanzhiGu,Zhiqiang Meng, Jieer Ying, Baocai Xing, Xianglin Yuan, Lindong Li, Sohail Mulla,Hui Shao, Beiying Ding, Ann-Lii Cheng

3.RC48-ADC 治疗HER2（IHC2+或IHC3+）局部晚期或转移性胃癌（包括胃食管

结合部腺癌）患者有效性和安全性的Ⅱ期临床研究

彭智，刘天舒，魏嘉，王爱蓉，何义富，杨留中，张西志，范南峰，罗素霞，龚继芳，李贞，顾康生，陆建伟，徐建明，樊青霞，徐瑞华，张良明，房建民，巴一，沈琳

4.白蛋白结合型紫杉醇联合替吉奥或吉西他滨联合替吉奥一线治疗局晚或转移性胰腺癌的随机、对照、多中心临床研究初步分析

郭曦，周宇红，楼文晖，庄荣源，纪元，吴莉莉，吕敏之，吴文川，傅德良，姚冽，张俊，

吴玮珺，刘静

5. Ibrutinib + Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone （RCHOP） in Patients With Untreated Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma （DLBCL）: a Chinese SubgroupAnalysis of the Phase 3 PHOENIX Trial 

Jun Zhu, Xiaonan Hong, Yu Qin Song, Sriram Balasubramanian, Songbai Wang,Brendan Hodkinson, Qingyuan Zhang, Yuankai Shi, Huiqiang Huang, Huilai Zhang, Yan Zhu, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Wyndham Wilson, Anas Younes

6. China-Manufactured Trastuzumab Biosimilar HLX02: Efficacy, Safety and Pharmacokinetics Comparison to Reference TZB in a Phase 3 Metastatic Breast Cancer Study

Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu, Igor Bondarenko,Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen

Wang, Hong Zheng,Zhongsheng Tong, Yaroslav Shparyk, Xinhong Wu, Herui Yao,

Yuping Sun, Huiping Li,Yunjiang Liu, Shuqun Zhang, Xiaohua Zeng, Ihor Vynnychenko, Xiaojia Wang, Yue Li,Ying Li, Weidong Jiang, Scott Liu, Katherine Chai

7.全人抗PD-L1 单克隆抗体ZKAB001 治疗复发转移性宫颈癌的Ⅱ期临床

安菊生，李贵玲，张阳，徐沁，宋红林，张云艳，王莉，唐洁，熊慧华，王丹波，邱惠，张红平，周琦，吴令英

编辑  中国医学论坛报  王淳